Product logins

Find logins to all Clarivate products below.


Sara Al-Zubeidi

Director, Commercial Strategy Consulting Global Pricing and Market Access

Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.

Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.

Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.

Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.

Related resources

支付方愿意为便利性买单的市场准入“最佳切入点” 支付方愿意为便利性买单的市场准入“最佳切入点”
Blog June 3, 2026
支付方愿意为便利性买单的市场准入“最佳切入点”
医疗保险 定价 市场准入 真实世界数据 美国市场 药政法规
2026 年值得关注的 5 大医疗技术趋势 2026 年值得关注的 5 大医疗技术趋势
Blog May 28, 2026
2026 年值得关注的 5 大医疗技术趋势
AI/机器学习 GLP-1 医疗技术 带量采购(VBP) 日间手术中心(ASC)
《2026年最值得关注的药物》问答:礼来的下一代减肥药 《2026年最值得关注的药物》问答:礼来的下一代减肥药
Blog March 26, 2026
《2026年最值得关注的药物》问答:礼来的下一代减肥药
GLP-1 最值得关注的药物
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学